No longer a molecular black box - New clues to apoptosis and drug resistance in melanoma

Kapaettu Satyamoorthy, Thomas Bogenrieder, Meenhard Herlyn

    Research output: Contribution to journalShort survey

    52 Citations (Scopus)

    Abstract

    Disseminated melanoma is a radiation- and chemotherapy-refractory neoplasm for which no standard therapy currently exists. So far, genetic and molecular studies have revealed few non-random chromosomal abnormalities and infrequent mutational spectra. Consequently, the precise molecular determinants responsible for melanoma progression are yet to be delineated. Recent studies, however, have identified defects at multiple levels of the apoptosis program in melanoma, which provided new clues to drug resistance of this highly aggressive neoplasm. The process of apoptosis provides a conceptual framework to link melanoma genetics with the outcome of melanoma therapy. Hence, the genes and proteins that control apoptosis provide exciting new targets for rationally designed anti-melanoma therapeutic strategies.

    Original languageEnglish
    Pages (from-to)191-194
    Number of pages4
    JournalTrends in Molecular Medicine
    Volume7
    Issue number5
    DOIs
    Publication statusPublished - 2001

    Fingerprint

    Drug Resistance
    Melanoma
    Apoptosis
    Chromosome Aberrations
    Molecular Biology
    Neoplasms
    Therapeutics
    Radiation
    Drug Therapy
    Proteins

    All Science Journal Classification (ASJC) codes

    • Medicine(all)

    Cite this

    @article{53d62b1bd89e455bb473e7fdf6b0560d,
    title = "No longer a molecular black box - New clues to apoptosis and drug resistance in melanoma",
    abstract = "Disseminated melanoma is a radiation- and chemotherapy-refractory neoplasm for which no standard therapy currently exists. So far, genetic and molecular studies have revealed few non-random chromosomal abnormalities and infrequent mutational spectra. Consequently, the precise molecular determinants responsible for melanoma progression are yet to be delineated. Recent studies, however, have identified defects at multiple levels of the apoptosis program in melanoma, which provided new clues to drug resistance of this highly aggressive neoplasm. The process of apoptosis provides a conceptual framework to link melanoma genetics with the outcome of melanoma therapy. Hence, the genes and proteins that control apoptosis provide exciting new targets for rationally designed anti-melanoma therapeutic strategies.",
    author = "Kapaettu Satyamoorthy and Thomas Bogenrieder and Meenhard Herlyn",
    year = "2001",
    doi = "10.1016/S1471-4914(01)02013-5",
    language = "English",
    volume = "7",
    pages = "191--194",
    journal = "Trends in Molecular Medicine",
    issn = "1471-4914",
    publisher = "Elsevier Limited",
    number = "5",

    }

    No longer a molecular black box - New clues to apoptosis and drug resistance in melanoma. / Satyamoorthy, Kapaettu; Bogenrieder, Thomas; Herlyn, Meenhard.

    In: Trends in Molecular Medicine, Vol. 7, No. 5, 2001, p. 191-194.

    Research output: Contribution to journalShort survey

    TY - JOUR

    T1 - No longer a molecular black box - New clues to apoptosis and drug resistance in melanoma

    AU - Satyamoorthy, Kapaettu

    AU - Bogenrieder, Thomas

    AU - Herlyn, Meenhard

    PY - 2001

    Y1 - 2001

    N2 - Disseminated melanoma is a radiation- and chemotherapy-refractory neoplasm for which no standard therapy currently exists. So far, genetic and molecular studies have revealed few non-random chromosomal abnormalities and infrequent mutational spectra. Consequently, the precise molecular determinants responsible for melanoma progression are yet to be delineated. Recent studies, however, have identified defects at multiple levels of the apoptosis program in melanoma, which provided new clues to drug resistance of this highly aggressive neoplasm. The process of apoptosis provides a conceptual framework to link melanoma genetics with the outcome of melanoma therapy. Hence, the genes and proteins that control apoptosis provide exciting new targets for rationally designed anti-melanoma therapeutic strategies.

    AB - Disseminated melanoma is a radiation- and chemotherapy-refractory neoplasm for which no standard therapy currently exists. So far, genetic and molecular studies have revealed few non-random chromosomal abnormalities and infrequent mutational spectra. Consequently, the precise molecular determinants responsible for melanoma progression are yet to be delineated. Recent studies, however, have identified defects at multiple levels of the apoptosis program in melanoma, which provided new clues to drug resistance of this highly aggressive neoplasm. The process of apoptosis provides a conceptual framework to link melanoma genetics with the outcome of melanoma therapy. Hence, the genes and proteins that control apoptosis provide exciting new targets for rationally designed anti-melanoma therapeutic strategies.

    UR - http://www.scopus.com/inward/record.url?scp=0034844645&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0034844645&partnerID=8YFLogxK

    U2 - 10.1016/S1471-4914(01)02013-5

    DO - 10.1016/S1471-4914(01)02013-5

    M3 - Short survey

    VL - 7

    SP - 191

    EP - 194

    JO - Trends in Molecular Medicine

    JF - Trends in Molecular Medicine

    SN - 1471-4914

    IS - 5

    ER -